Columbia Laboratories, Inc. Buyback
OLI recorded this information on 3/7/2014
Columbia Laboratories, Inc.
Shares Announced Repurchased:
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding shares of common stock by about 11.5% from approximately 12.15 million to 10.75 million.
Juniper Pharmaceuticals is engaged in in the business of developing, licensing, manufacturing and selling to its marketing partners pharmaceutical products that utilize its drug delivery technologies to treat various medical conditions. Co.'s products include bioadhesive vaginal gel products for infertility, pregnancy support, amenorrhea, and other women's health conditions, and a bioadhesive buccal system for male hypogonadism. Co. has partnered or sold each of these products for commercialization in various regions of the world. All of the products Co. has developed utilize its Bioadhesive Delivery System, which consists principally of a polymer (polycarbophil) and an active ingredient.
Open the CBRX Page at The Online Investor »
Free CBRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Buy (3.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite